+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

  • ID: 4462166
  • Report
  • May 2021
  • Region: Global
  • 45 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2017, there were approximately 15,200 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 18,060 incident cases by 2026.
  • In 2017, there were approximately 5,930 incident cases of CTCL in the US and five major European markets (France, Germany, Italy, Spain, and the UK), which is forecast to increase to 6,160 incident cases by 2026.
  • The publisher estimates that there were approximately 41,900 10-year prevalent cases of CTCL in the US and five major European markets in 2017, which is expected to increase to 45,030 cases by 2026.
  • Approved drugs in the CTCL space target antibody-drug conjugate, cluster of differentiation 30, tumor necrosis factor receptor superfamily member 8, microtubules, histone deacetylase, interleukin-2, protein synthesis, chemokine receptor 4, retinoid X receptors, retinoid receptors, DNA, and DNA synthesis. These drugs are administered via the intravenous, topical, and oral routes.
  • The majority of industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only one drug in Phase III. Therapies in development for CTCL focus on a wide variety of targets. The greatest proportion of pipeline drugs in development are administered intravenously, with the remainder being tested in oral, topical, and intratumoral formulations.
  • High-impact upcoming events for drugs in the CTCL space comprise topline Phase II trial results for resminostat and IPH4102. The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for CTCL have been in the early and mid-phases of development, with 88% of trials in Phase I–II, and only 12% in Phase III–IV.
  • The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the CTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for CTCL, with six trials. Bristol Myers Squibb also leads industry sponsors with the highest overall number of clinical trials for CTCL, followed by Merck & Co.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Skin-directed therapy
  • Systemic therapy
EPIDEMIOLOGY
  • Incidence methodology for the US and five major European markets
  • Prevalence methodology for the US and five major European markets
MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • HyBryte for CTCL (October 22, 2020)
  • Cobomarsen for CTCL (October 5, 2020)
  • HyBryte for CTCL (April 30, 2020)
  • HyBryte for CTCL (March 19, 2020)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • No English Funding For Lymphoma Drugs Ledaga and Poteligeo
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Kyowa Kirin Bags China Rights To Helsinn’s Chlormethine
  • Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Global trends in incident cases of CTCL, 2017–26
Figure 2: Trends in incident cases of CTCL, US and 5 Euro, 2017–26
Figure 3: Overview of pipeline drugs for CTCL in the US
Figure 4: Pipeline drugs for CTCL, by company
Figure 5: Pipeline drugs for CTCL, by drug type
Figure 6: Pipeline drugs for CTCL, by classification
Figure 7: HyBryte for CTCL (April 30, 2020): Phase III - FLASH
Figure 8: HyBryte for CTCL (March 19, 2020): Phase III - FLASH
Figure 9: Key upcoming events in CTCL
Figure 10: Probability of success in the hematologic pipeline
Figure 11: Clinical trials in CTCL
Figure 12: Top 10 drugs for clinical trials in CTCL
Figure 13: Top 10 companies for clinical trials in CTCL
Figure 14: Trial locations in CTCL
Figure 15: CTCL trials status
Figure 16: CTCL trials sponsors, by phase

LIST OF TABLES
Table 1: Global incident cases of CTCL, 2017–26
Table 2: Incident cases of CTCL, US and 5 Euro, 2017–26
Table 3: 10-year prevalent cases of CTCL, US and 5 Euro, 2017–26
Table 4: Five-year prevalent cases of CTCL, US and 5 Euro, 2017–26
Table 5: Marketed drugs for CTCL
Table 6: Pipeline drugs for CTCL in the US
Table 7: HyBryte for CTCL (October 22, 2020)
Table 8: Cobomarsen for CTCL (October 5, 2020)
Table 9: HyBryte for CTCL (April 30, 2020)
Table 10: HyBryte for CTCL (March 19, 2020)
Table 11: Historical global sales, by drug ($m), 2016–20
Table 12: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll